Literature DB >> 33511518

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.

Arefeh Basiri1,2, Fatemeh Mansouri2,3,4, Arezo Azari2,5, Parviz Ranjbarvan2,6, Fateme Zarein2,7, Arash Heidari2,8, Ali Golchin9,10.   

Abstract

Currently, there are no specific and efficient vaccines or drugs for COVID-19, particularly in severe cases. A wide range of variations in the clinical symptoms of different patients attributed to genomic differences. Therefore, personalized treatments seem to play a critical role in improving these symptoms and even similar conditions. Prompted by the uncertainties in the area of COVID-19 therapies, we reviewed the published papers and concepts to gather and provide useful information to clinicians and researchers interested in personalized medicine and cell-based therapy. One novel aspect of this study focuses on the potential application of personalized medicine in treating severe cases of COVID-19. However, it is theoretical, as any real-world examples of the use of genuinely personalized medicine have not existed yet. Nevertheless, we know that stem cells, especially MSCs, have immune-modulatory effects and can be stored for future personalized medicine applications. This theory has been conjugated with some evidence that we review in the present study. Besides, we discuss the importance of personalized medicine and its possible aspects in COVID-19 treatment, then review the cell-based therapy studies for COVID-19 with a particular focus on stem cell-based therapies as a primary personalized tool medicine. However, the idea of cell-based therapy has not been accepted by several scientific communities due to some concerns of lack of satisfactory clinical studies; still, the MSCs and their clinical outcomes have been revealed the safety and potency of this therapeutic approach in several diseases, especially in the immune-mediated inflammatory diseases and some incurable diseases. Promising outcomes have resulted in that clinical studies are going to continue.

Entities:  

Keywords:  COVID-19; Cell-based therapy; Personalized medicine; Stem cell

Mesh:

Year:  2021        PMID: 33511518      PMCID: PMC7842180          DOI: 10.1007/s12015-020-10110-w

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  131 in total

1.  The association of interferon-gamma, interleukin-4 and interleukin-17 single-nucleotide polymorphisms with susceptibility to tuberculosis.

Authors:  Fatemeh Mansouri; Rasoul Heydarzadeh; Saber Yousefi
Journal:  APMIS       Date:  2018-01-25       Impact factor: 3.205

2.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.

Authors:  Guangwen Ren; Liying Zhang; Xin Zhao; Guangwu Xu; Yingyu Zhang; Arthur I Roberts; Robert Chunhua Zhao; Yufang Shi
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

3.  Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.

Authors:  Sairam Atluri; Laxmaiah Manchikanti; Joshua A Hirsch
Journal:  Pain Physician       Date:  2020-03       Impact factor: 4.965

4.  Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection.

Authors:  Robert F Foronjy; Abdoulaye J Dabo; Neville Cummins; Patrick Geraghty
Journal:  BMC Immunol       Date:  2014-10-03       Impact factor: 3.615

5.  Mesenchymal Stem Cells and Induced Bone Marrow-Derived Macrophages Synergistically Improve Liver Fibrosis in Mice.

Authors:  Yusuke Watanabe; Atsunori Tsuchiya; Satoshi Seino; Yuzo Kawata; Yuichi Kojima; Shunzo Ikarashi; Philip J Starkey Lewis; Wei-Yu Lu; Junichi Kikuta; Hirokazu Kawai; Satoshi Yamagiwa; Stuart J Forbes; Masaru Ishii; Shuji Terai
Journal:  Stem Cells Transl Med       Date:  2018-11-05       Impact factor: 6.940

Review 6.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.

Authors:  Margaret A Liu
Journal:  Vaccines (Basel)       Date:  2019-04-24

7.  Novel genotype of infectious bronchitis virus isolated in China.

Authors:  Tianxin Ma; Liwen Xu; Mengting Ren; Jie Shen; Zongxi Han; Junfeng Sun; Yan Zhao; Shengwang Liu
Journal:  Vet Microbiol       Date:  2019-01-29       Impact factor: 3.293

Review 8.  Stem cell therapy in coronavirus disease 2019: current evidence and future potential.

Authors:  Rohit Shetty; Ponnalagu Murugeswari; Koushik Chakrabarty; Chaitra Jayadev; Himanshu Matalia; Arkasubhra Ghosh; Debashish Das
Journal:  Cytotherapy       Date:  2020-11-09       Impact factor: 5.414

9.  Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.

Authors:  Jiajia Chen; Chenxia Hu; Lijun Chen; Lingling Tang; Yixin Zhu; Xiaowei Xu; Lu Chen; Hainv Gao; Xiaoqing Lu; Liang Yu; Xiahong Dai; Charlie Xiang; Lanjuan Li
Journal:  Engineering (Beijing)       Date:  2020-02-28       Impact factor: 7.553

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  9 in total

Review 1.  Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.

Authors:  Saman Yasamineh; Hesam Ghafouri Kalajahi; Pooneh Yasamineh; Omid Gholizadeh; Hamed Rahmani Youshanlouei; Saeed Karimi Matloub; Masoud Mozafari; Elham Jokar; Yalda Yazdani; Mehdi Dadashpour
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

2.  Human Wharton's Jelly Mesenchymal Stem Cells Secretome Inhibits Human SARS-CoV-2 and Avian Infectious Bronchitis Coronaviruses.

Authors:  Mohamed A A Hussein; Hosni A M Hussein; Ali A Thabet; Karim M Selim; Mervat A Dawood; Ahmed M El-Adly; Ahmed A Wardany; Ali Sobhy; Sameh Magdeldin; Aya Osama; Ali M Anwar; Mohammed Abdel-Wahab; Hussam Askar; Elsayed K Bakhiet; Serageldeen Sultan; Amgad A Ezzat; Usama Abdel Raouf; Magdy M Afifi
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

Review 3.  Potential therapeutic options for COVID-19: an update on current evidence.

Authors:  Zahra Niknam; Ameneh Jafari; Ali Golchin; Fahima Danesh Pouya; Mohadeseh Nemati; Mostafa Rezaei-Tavirani; Yousef Rasmi
Journal:  Eur J Med Res       Date:  2022-01-13       Impact factor: 2.175

Review 4.  A comprehensive review on efficient approaches for combating coronaviruses.

Authors:  Mahdi Pouresmaieli; Elena Ekrami; Ali Akbari; Negin Noorbakhsh; Negin Borzooee Moghadam; Matin Mamoudifard
Journal:  Biomed Pharmacother       Date:  2021-10-22       Impact factor: 6.529

Review 5.  Nanotechnology-based products for cancer immunotherapy.

Authors:  Forough Shams; Ali Golchin; Arezo Azari; Leila Mohammadi Amirabad; Fateme Zarein; Atiyeh Khosravi; Abdolreza Ardeshirylajimi
Journal:  Mol Biol Rep       Date:  2021-10-29       Impact factor: 2.742

Review 6.  Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.

Authors:  Lijun Chen; Jingjing Qu; Farhin Shaheed Kalyani; Qi Zhang; Lingzhi Fan; Yangxin Fang; Yifei Li; Charlie Xiang
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

Review 7.  Significance of Cardiac Troponins as an Identification Tool in COVID-19 Patients Using Biosensors: An Update.

Authors:  Yousef Rasmi; Osama F Mosa; Shahriar Alipour; Nadia Heidari; Farzaneh Javanmard; Ali Golchin; Shiva Gholizadeh-Ghaleh Aziz
Journal:  Front Mol Biosci       Date:  2022-02-24

8.  Immunomodulating Profile of Dental Mesenchymal Stromal Cells: A Comprehensive Overview.

Authors:  Alessia Paganelli; Oriana Trubiani; Francesca Diomede; Alessandra Pisciotta; Roberto Paganelli
Journal:  Front Oral Health       Date:  2021-03-31

9.  COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?

Authors:  Jean Jacques Vanden Eynde
Journal:  Pharmaceuticals (Basel)       Date:  2021-07-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.